Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061)

Tools
- Tools
+ Tools

Abdelraouf, F., Smit, E., Hasan, B., Menis, J., Popat, S., van Meerbeeck, J. P., Surmont, V. F., Baas, P., O'Brien, M. (2016) Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061). EUROPEAN JOURNAL OF CANCER, 54. pp. 35-39. ISSN 0959-8049

Full text not available from this repository.

Abstract

Background: Targeted therapies have to date not been successful in the treatment of small cell lung cancer (SCLC). This study aimed to assess the therapeutic activity of sunitinib (an oral, multi-targeted tyrosine kinase inhibitor) using positron emission tomography (PET)-computed tomography (CT) imaging as an early indicator of response. Methods: This was a single-arm phase II study of sunitinib in patients with SCLC who are either chemo naive (extensive disease) or have a 'sensitive' relapse. A loading dose of 150 mg sunitinib was given orally followed by 37.5 mg/d. The primary end-point was disease control rate (DCR) at 8 weeks after the start of treatment and secondary end-points included toxicity of treatment and overall response. PET-CT was carried out at 4 weeks into the treatment. The study was closed early because of low accrual with only 9 of required 48 patients (19%) accrued. Results: Nine patients were registered, seven females and two males with a median age of 65 years and a median duration of sunitinib treatment of 7.4 weeks. DCR at 8 weeks was achieved in two patients, both of whom went on to long periods of disease control, one patient achieved a partial response which lasted 10 months and a second patient had stable disease (minor shrinkage) which lasted 20 months. One of these patients proved to have an atypical carcinoid tumour at rebiopsy after 10 months. DCR and PET-CT imaging both predicted these responses. Grade III-IV toxicities were encountered during treatment, most commonly neutropenia (n = 3), thrombocytopenia (n = 3) and hypermagnesaemia (n = 2). One toxic death occurred due to bronchial haemorrhage. Conclusion: This study emphasises the need for alternate study design and end-points for new drug assessment in SCLC. EudraCT number: 2006-002485-19. (C) 2015 Elsevier Ltd. All rights reserved.

Item Type: Article
All Authors: Abdelraouf, F., Smit, E., Hasan, B., Menis, J., Popat, S., van Meerbeeck, J. P., Surmont, V. F., Baas, P., O'Brien, M.
Additional Information: ISI Document Delivery No.: DC3WQ Times Cited: 0 Cited Reference Count: 6 Abdelraouf, Fatma Smit, Egbert Hasan, Baktiar Menis, Jessica Popat, Sanjay van Meerbeeck, Jan P. Surmont, Veerle F. Baas, Paul O'Brien, Mary 0 ELSEVIER SCI LTD OXFORD EUR J CANCER
Uncontrolled Keywords: SCLC Sunitinib Tyrosine kinase inhibitor Targeted therapy Phase II study Second-line treatment MAINTENANCE SUNITINIB CHEMOTHERAPY
Research teams: Clinical Units > Lung Unit
Depositing User: Barry Jenkins
Date Deposited: 23 Feb 2016 11:02
Last Modified: 23 Feb 2016 11:02
URI: http://publications.icr.ac.uk/id/eprint/14805

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust